Predictive Role of Leptin Receptor (Ob-R) Overexpression in Patients with Early Breast Cancer Receiving Neoadjuvant Systemic Treatment

• Published in: Cancers Vol. 13; no. 13; p. 3269
• Main Authors: García-Estévez, Laura, Calvo, Isabel, Pérez, Silvia, Gallegos, Isabel, Díaz, Eva, Sampayo-Cordero, Miguel, Oltra, Sara S, Moreno-Bueno, Gema
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 29-06-2021; MDPI
• Subjects: Angiogenesis; Biobanks; Biomarkers; Body mass index; Body weight; Breast cancer; Cancer therapies; Chemotherapy; ErbB-2 protein; Growth factors; Immunohistochemistry; Kinases; Mammography; Menopause; Metastasis; Monoclonal antibodies; Pandemics; Patients; Tumorigenesis; Tumors; United States > US; Germany
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13133269

The primary aim of this retrospective study was to investigate the correlation between the immunohistochemical expression of Ob-R (leptin receptor) with pCR (pathological complete response) in early breast cancer patients receiving neoadjuvant systemic treatment (NST). A total of 100 women with breast cancer receiving NST (2017–2020) followed by surgical resection were retrospectively obtained. Demographic parameters and clinicopathological factors (e.g., treatment modalities, immunohistochemistry (IHC), and cancer subtype) were obtained from the patient’s clinical records. In the analyzed breast cancer cohort, high expression of Ob-R was found in 52% of tumors and there was a significantly higher incidence in the HER2+ and TNBC subgroups. Overall, a significantly greater percentage of patients with Ob-R positive tumors achieved pCR compared with Ob-R negative patients (57.7% vs. 27.1%; p = 0.002). This result was observed in most breast cancer subtypes. In patients with HER2+ breast cancer, there was no difference in Ob-R expression in relation to the HR status. Ob-R cell positivity was significantly higher in younger breast cancer patients (p = 0.008), those who were premenopausal (p = 0.011), and in those with a BMI > 25 kg/m2 (p = 0.019). A significantly greater percentage of early breast cancer patients with Ob-R positive tumors achieved pCR compared with Ob-R negative patients. Furthermore, breast cancer patients with positive Ob-R expression were significantly younger than those with negative Ob-R expression. This association was not explained by differences in BMI between young and old patients.